Asthma treatment

http://www.healasthma.com past six monthsthe past twelve months Search Hint Connecting terms with OR broadens your search to give more results …more on search operators – . Asthma sufferers will pay more for their inhalers Asthma sufferers who rely on fast-acting “rescue inhalers” soon be scrambling to find the gadgets that help quell their sudden, agonizing attacks. The inhalers, which propel medicine into users’ airways, are in short supply at some hospitals and pharmacies across the country. And their availability is expected to worsen, as drugmakers make a switch from the traditional devices to inhalers that are more environmentally friendly.The shortage… . Sun-Sentinel – BUSINESS BRIEFING Andrx sells Massachusetts unit.Andrx Corp. sold its Massachusetts aerosol manufacturing operations, ending the company’s production of Albuterol metered-dose inhalers after continued underutilized capacity at the plant.The Davie-based drug company sold the aerosol inhaler-making unit, Armstrong Pharmaceuticals, to Amphastar Pharmaceuticals Inc., a California-based generic and specialty pharmaceutical maker.The deal calls for Andrx to buy certain amounts of Albuterol inhalers… CFC-free asthma drugs, Green inhalers It won’t happen overnight. But global treaties curbing ozone-depleting chlorofluorocarbons, or CFCs, have spurred the U.S. Food and Drug Administration to propose a strategy for phasing out asthma inhalers that use CFCs as propellants. Under the plan, to be announced in four to six weeks, the devices will be removed from the market and be replaced by new CFC-free formulations. The first to be replaced be Schering’s Proventil (albuterol), one of the drugs… Business Briefcase BREATHING EASY Sepracor Inc. of Marlboro said yesterday it recently presented data showing its anti-asthma drug candidate R-albuterol fought the disease successfully at dosages producing far fewer side effects than other albuterol therapies. OVERHAUL Two senators will introduce a bill Monday to overhaul federal commodity trading laws and ease federal oversight of the nation’s futures exchanges. The bill won’t contain language to rewrite the so-called… New inhalers protect ozone layer, They’re more costly, take getting used to, asthma patients find Asthmatics are going green, whether they know it or not.And they are forking over the green to do it.The Food and Drug Administration’s ban on the sale of rescue inhalers that use chlorofluorocarbons, or CFCs, which damage Earth’s protective ozone layer, takes effect Wednesday.The green rescue inhalers use the chemical hydrofluoroalkane, or HFA, in place of CFCs, to pump medicine to open the airways during an asthma attack. The medicine inside the… . Datamonitor – AstraZeneca’s Symbicort found effective in comparative study AstraZeneca has reported positive data from a new study which showed that the combination asthma maintenance therapy, Symbicort has provided greater and faster bronchodilatory effects compared with Advair in adults with mild to moderate asthma. In addition, Symbicort has provided a similar bronchodilatory response to albuterol. Bronchodilatory response is defined as the mean time to achieve improvement in lung function. In both studies, bronchodilatory response was measured by the… . FD (FAIR DISCLOSURE) WIRE – Q Sepracor Earnings Conference Call – Final OPERATOR Welcome to Sepracor’s fourth-quarter and full-year earnings conference call. Hosting the call today from Sepracor is Mr. Adrian Adams, President and Chief Executive Officer. At this time all participants have been placed in a listen-only mode and the floor will be open for your questions following the presentation. (OPERATOR INSTRUCTIONS) It is now my pleasure to turn the floor over to your host, Mr. Adrian Adams. Sir, you begin.ADRIAN ADAMS, PRESIDENT… . FD (FAIR DISCLOSURE) WIRE – Event Brief of Q Teva Pharmaceutical Earnings Conference Call – Final PARTICIPANTS . Kevin Mannix, Teva Pharmaceutical Industries Ltd., Investor Relations . Shlomo Yanai, Teva Pharmaceutical Industries Ltd., President & CEO . George Barrett, Teva Pharmaceutical Industries Ltd., Corporate EVP, Global Pharmaceutical Markets and President & CEO – Teva North America . Dan Suesskind, Teva Pharmaceutical Industries Ltd., CFO . David Buck, Buckingham Research Group, Analyst . Rich Silver, Lehman Brothers, Analyst . Corey… . FD (FAIR DISCLOSURE) WIRE – Q Teva Pharmaceutical Earnings Conference Call – Final OPERATOR Greetings, ladies and gentlemen, and welcome to the Teva Pharmaceutical Industries Ltd. second quarter results conference call. At this time all participants are in a listen-only mode. A brief question-and-answer session will follow the formal presentation. (OPERATOR INSTRUCTIONS) As a reminder, this conference is being recorded. It is my pleasure to introduce your host, Mr. Kevin Mannix. Thank you, you begin. KEVIN MANNIX, INVESTOR RELATIONS, TEVA PHARMACEUTICAL… Consider the patient This letter was addressed to Congressman Wayne T. Gilchrest, R-Md.- st.Re Petition before the Food and Drug Administration to remove “Albuterol” inhaler presently effective and available as a generic with an alternate with no known improvement but available at a percent increase in cost.Albuterol delivered via an inhaler is used by millions to enable asthmatics, emphysema and assorted other lung disease patients. The inhaler has been on the market in… –